ArticlePsychopharmacology2025
Optimizing prenatal valproic acid exposure in zebra finches to model autism-related phenotypes.
Article in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
rationaleRodent models dominate autism spectrum disorder (ASD) research, yet their translational validity is limited for a heterogeneous condition with complex social-vocal phenotypes.
objectivesTo evaluate the zebra finch (Taeniopygia guttata) - a highly social, vocal-learning songbird - as an ASD model by adapting embryonic valproic acid (VPA) exposure and identifying dose-timing conditions that preserve viability while perturbing social behavior.
methodsWe used a 3 × 3 design crossing VPA dose (0, 0.3, 0.6 µmol/egg) with manipulation day (incubation days 8-10). Hatching success, post-hatching survival, growth, and social behavior in a bird-adapted three-chamber test were quantified with mixed-effects models (binomial/Cox/linear/negative binomial, beta-binomial).
resultsHatching success decreased at 0.6 µmol and with day-8 injections; day-9 performed best. Post-hatching survival was lower at 0.3 µmol versus controls (limited inference for 0.6 µmol due to small n). Growth showed dose×sex interactions: females at 0.6 µmol were lighter with shorter tarsi; wings showed a similar tendency. In sociability (phase 1), time-based measures were unchanged, 0.6-µmol birds made more approaches to the closest perch, while day-8 birds approached less than day-9. In phase 2, time on the familiar-side closest perch showed a day×sex interaction (day-8 females spent less time than day-8 males), and approaches to that perch increased at 0.6 µmol. Overall sociability (combined closest perches) and total activity did not differ by group.
conclusionsEmbryonic VPA in zebra finches yields selective, partly sex-dependent developmental and social effects. Zebra finches remain promising; day-9 intermediate doses (~ 0.35-0.50 µmol) warrant follow-up to map dose-response and balance viability with behavioral detectability.
Indexed as
Identifiers
41313438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.